Home Genetic Testing Basics Mitochondrial DNA (mtDNA) Test: Mutations, Inheritance, and Results

Genetic Testing Basics

Mitochondrial DNA (mtDNA) Test: Mutations, Inheritance, and Results

July 31, 2026 Modified date: July 31, 2026

Understand what an mtDNA test detects, how heteroplasmy and tissue choice affect results, what maternal inheritance means, and what to do after a positive, uncertain, or negative finding.

A mitochondrial DNA test looks for harmful changes in the small circle of DNA inside mitochondria, the energy-producing structures found in nearly every cell. The test can help diagnose mitochondrial disease, clarify a known family mutation, or estimate whether relatives may have inherited the same change. Its results are often more complex than a simple positive or negative answer because each cell contains many copies of mitochondrial DNA. A person may carry a mixture of changed and unchanged copies, called heteroplasmy, and the proportion can differ among blood, urine, muscle, and other tissues.

An mtDNA result therefore must be interpreted alongside symptoms, family history, the tested tissue, and the laboratory’s detection limits. A negative blood test does not always rule out an mtDNA disorder, especially when the variant level is low in blood or declines with age. Testing may also need to include nuclear genes because most proteins required for mitochondrial function are encoded outside the mitochondrial genome.

An mtDNA test can detect single-letter variants, small insertions or deletions, and—when specifically designed—large deletions or mtDNA copy-number abnormalities.
A pathogenic mtDNA variant may be present in all tested copies (homoplasmy) or only a percentage of them (heteroplasmy).
Variant percentage does not translate into one universal symptom threshold; effects depend on the specific variant, tissue, age, and organ system.
Blood is convenient, but urine sediment, cheek cells, or muscle may be more informative for some suspected disorders.
A negative mtDNA result does not exclude mitochondrial disease or a disease caused by a nuclear gene.
Maternal relatives may be at risk when a disease-causing mtDNA variant is inherited, but the severity can vary greatly within one family.

What an mtDNA Test Examines
Why mtDNA Testing Is Ordered
Samples and Testing Methods
How to Read mtDNA Test Results
Heteroplasmy, Thresholds, and Tissue Effects
Maternal Inheritance and Family Risk
Next Steps After Testing

What an mtDNA Test Examines

Mitochondria convert energy from food into adenosine triphosphate, or ATP, which cells use to perform most of their work. They contain their own genome, separate from the DNA packaged in the cell nucleus. Human mitochondrial DNA is about 16,569 DNA letters long and contains 37 genes: 13 encode parts of the respiratory-chain machinery, 22 encode transfer RNAs, and two encode ribosomal RNAs needed to make mitochondrial proteins.

That compact genome is only one part of mitochondrial biology. More than 1,000 nuclear genes contribute to mitochondrial structure, energy production, protein assembly, DNA maintenance, and other functions. For that reason, an “mtDNA test” is narrower than a complete evaluation for mitochondrial disease. It directly examines the mitochondrial genome, while a mitochondrial disease panel, whole-exome sequencing, or whole-genome sequencing may also evaluate relevant nuclear genes.

Clinical mtDNA tests may look for several kinds of changes:

Single-nucleotide variants: one DNA letter is replaced by another, such as the well-known m.3243A>G variant associated with MELAS and other presentations.
Small insertions or deletions: a short stretch of DNA is added or missing.
Large deletions: hundreds or thousands of DNA letters are absent. Single large-scale deletions can cause conditions such as Kearns-Sayre syndrome, Pearson syndrome, or chronic progressive external ophthalmoplegia.
Duplications or rearrangements: sections of mtDNA are repeated or reorganized.
Depletion: the total number of mtDNA copies is abnormally low in a tissue. Depletion usually results from pathogenic variants in nuclear genes that control mtDNA replication or maintenance, so it requires copy-number measurement and often nuclear-gene testing rather than sequence analysis alone.
Multiple deletions: numerous different deleted mtDNA molecules are present, often because of a nuclear-gene defect affecting mtDNA maintenance.

The scope matters. A targeted test for one familial variant will not search the entire mitochondrial genome. Full mtDNA sequencing may identify point variants and small changes but may not reliably detect low-level heteroplasmy, large rearrangements, or depletion unless the laboratory validates those analyses. The report’s methodology and limitations section identifies what the test could and could not detect.

Ancestry tests also analyze mtDNA, but their purpose is different. They usually assign a maternal haplogroup or estimate deep maternal ancestry. They are not a substitute for clinical testing, do not necessarily use medical-grade confirmation, and may report common population variants without establishing whether a change causes disease.

Why mtDNA Testing Is Ordered

Clinicians may consider mtDNA testing when symptoms suggest impaired cellular energy production, especially when several high-energy organs are involved. The brain, skeletal muscle, heart, eyes, inner ear, endocrine system, liver, and kidneys can be particularly vulnerable. No single symptom proves mitochondrial disease, and many more common conditions can produce similar findings.

Features that may prompt evaluation include:

unexplained muscle weakness, exercise intolerance, or fatigue with objective neuromuscular findings;
drooping eyelids or limited eye movement;
hearing loss, optic-nerve disease, or retinal changes;
seizures, developmental regression, ataxia, movement disorders, or stroke-like episodes that do not follow a typical blood-vessel territory;
cardiomyopathy or cardiac conduction problems;
diabetes combined with hearing loss or a maternal family pattern;
recurrent unexplained lactic acidosis;
liver failure, kidney tubule dysfunction, or severe multisystem illness in infancy;
a combination of otherwise unexplained findings across several organs; or
relatives on the maternal side with compatible symptoms.

A test may serve different clinical goals. Diagnostic testing looks for the cause of current symptoms. Targeted familial testing checks whether a relative carries a specific variant already identified in the family. Reproductive testing helps assess transmission risk before or during pregnancy. Some laboratories also evaluate mtDNA as part of broad genomic testing when the diagnosis is unclear.

The order of testing depends on the presentation. A person with a classic syndrome and a well-established common variant may begin with targeted analysis, although full mitochondrial-genome sequencing is increasingly preferred because symptoms overlap and a limited assay can miss other causes. Someone with a nonspecific multisystem disorder may benefit from concurrent analysis of mtDNA and nuclear genes. This broader approach can prevent a false assumption that all mitochondrial disease follows maternal inheritance.

Testing can provide more than a diagnostic label. A confirmed molecular diagnosis may guide organ surveillance, identify medicines or exposures that require extra caution, prevent repeated invasive investigations, connect a person with condition-specific care, and clarify who else in the family should be offered testing. It may also make someone eligible for a clinical study. However, treatment is usually based on the person’s manifestations as well as the gene result; the same mtDNA variant can lead to different needs in different people.

Genetic counseling is especially helpful before testing when the possible outcomes may affect several relatives or reproductive plans. It gives the person a chance to discuss uncertain results, privacy, insurance considerations, incidental findings from broader tests, and whether they want information that may not change current medical care.

Samples and Testing Methods

The sample is not merely a collection detail in mtDNA testing. It can determine whether a variant is detectable.

Blood is often used first because collection is simple. Yet some pathogenic mtDNA variants become less abundant in white blood cells over time. A low or undetectable level in an adult’s blood may therefore underestimate what is present in muscle, brain, urinary cells, or other affected tissues. For certain variants, urine epithelial cells can provide a more sensitive noninvasive sample. Cheek cells, hair follicles, skin fibroblasts, or muscle may also be considered depending on the suspected condition and prior results.

Muscle biopsy used to be central to mitochondrial diagnosis because it allows histology, respiratory-chain studies, and DNA analysis from a highly energy-dependent tissue. Modern genomic testing has reduced the need for biopsy, but muscle can remain valuable when blood and urine testing are unrevealing, a large deletion or low-level mosaic change is suspected, or functional evidence is needed. A biopsy is an invasive procedure and should be planned with a specialist so the specimen is collected and handled for the intended biochemical and molecular studies.

Common laboratory approaches include:

Method	Best suited for	Important limitation
Targeted variant analysis	A known family variant or a small set of common variants	Does not evaluate most of the mitochondrial genome
Next-generation mtDNA sequencing	Broad detection of single-letter variants and small changes, with heteroplasmy measurement	Detection threshold and coverage vary by laboratory
Deletion or duplication analysis	Large-scale mtDNA rearrangements	Blood may miss a deletion concentrated in muscle or another tissue
mtDNA copy-number analysis	Suspected depletion or abnormal mtDNA abundance	Usually requires an appropriate affected tissue and does not identify the nuclear cause by itself
Dual-genome panel, exome, or genome analysis	Overlapping phenotypes that may arise from mtDNA or nuclear genes	Some assays have uneven mtDNA coverage or do not validate low heteroplasmy

Next-generation sequencing can read the mitochondrial genome thousands of times, allowing the laboratory to estimate the fraction of sequence reads carrying a variant. A report might state 28% heteroplasmy in blood or 64% in urine. That number is an analytical estimate, not a direct measure of the percentage of affected cells, and it has a margin of error. Laboratories also set a lower reporting threshold—commonly a few percent, though the exact limit differs by assay and variant type.

Technical artifacts can arise because pieces of mtDNA have been copied into nuclear chromosomes over evolutionary time. These sequences, called NUMTs, can be mistaken for true mitochondrial variants if an assay or analysis pipeline does not distinguish them. Accredited clinical laboratories use validated methods and confirmation strategies to reduce this risk.

Before collection, ask what tissues the laboratory accepts, whether its assay detects heteroplasmy and large deletions, and whether mtDNA analysis is performed directly or inferred from exome or genome data. Those details are especially important after an earlier negative test.

How to Read mtDNA Test Results

An mtDNA report combines two separate judgments: what variant was found and how strongly current evidence links it to disease. The result may be described as positive, negative, uncertain, carrier-like, or inconclusive, but the detailed classification is more informative than the headline.

Pathogenic or likely pathogenic result

A pathogenic or likely pathogenic variant has enough evidence to support a disease association. The report should name the variant using mitochondrial nomenclature, identify the gene, state the tested tissue, and provide the measured heteroplasmy when relevant. For example, “m.3243A>G in MT-TL1, 22% heteroplasmy in blood” communicates much more than “positive.”

A disease-causing classification does not automatically prove that every symptom comes from the variant. The clinician still considers whether the person’s manifestations fit the known spectrum, whether another diagnosis is present, and whether the detected level and tissue are informative. Some mtDNA variants have reduced penetrance: a person can carry the change without developing the classic disorder. Others produce a wide range of severity.

When the result explains the presentation, the next steps may include baseline evaluation of hearing, vision, heart rhythm and structure, neurologic status, glucose regulation, kidney or liver function, and other organs linked to that condition. Surveillance should be tailored rather than applied as one universal mitochondrial checklist.

Variant of uncertain significance

A variant of uncertain significance, or VUS, means available evidence cannot yet show whether the change is harmful or benign. A VUS should not be treated as a confirmed diagnosis, used alone to predict disease in a healthy relative, or drive irreversible reproductive or medical decisions.

The laboratory may examine how common the variant is in population databases, whether it changes a conserved part of a gene, whether it has been reported in affected people, whether it segregates with symptoms in a family, its heteroplasmy pattern, and any functional studies. Because mtDNA interpretation also depends on haplogroup background and tissue distribution, computational predictions alone are not enough.

Testing selected relatives can sometimes clarify a VUS, but indiscriminate family testing may add little. A genetics professional can identify which relatives and tissues would be informative. Laboratories may reclassify variants as evidence changes, so the ordering clinic should keep current contact information and periodically ask about reinterpretation.

Benign or likely benign finding

Benign and likely benign variants are not considered disease-causing. Every person has many mtDNA differences compared with the reference sequence, and most reflect normal human variation or maternal ancestry. Clinical reports may omit benign changes or list them separately. A common haplogroup marker should not be mistaken for a mutation that explains illness.

Negative result

A negative result means the assay did not find a reportable disease-causing variant within the regions and variant types it evaluated. It does not mean the person has “normal mitochondria,” and it does not rule out all mitochondrial disease.

A negative test may occur because:

the causal mtDNA variant is below the assay’s detection threshold;
the tested tissue contains little or none of the variant;
the test did not assess large deletions, depletion, or another relevant change type;
a nuclear gene causes the disorder;
the disease gene or variant has not yet been recognized;
the symptoms arise from a nonmitochondrial condition; or
the clinical diagnosis is correct but current technology cannot demonstrate the cause.

The report’s “limitations” section should guide follow-up. The next test may be a different tissue, deletion analysis, copy-number measurement, a nuclear mitochondrial panel, exome or genome sequencing, RNA analysis, biochemical testing, or a reassessment of the original diagnosis.

Heteroplasmy, Thresholds, and Tissue Effects

Heteroplasmy is the coexistence of more than one mtDNA sequence within a cell or person. Because cells contain hundreds to thousands of mtDNA molecules, a pathogenic variant can occupy a small fraction, most copies, or anything in between. Homoplasmy means nearly all detectable copies carry the same sequence, whether that sequence is benign or pathogenic.

The proportion can shift when cells divide, across tissues, and over a lifetime. This biological sorting helps explain why a mother and child with the same named mtDNA variant may have very different symptoms. It also explains why blood, urine, and muscle can return different percentages from the same person.

A threshold effect occurs when the burden of dysfunctional mitochondria in a tissue becomes high enough to impair energy production. There is no single threshold that applies to every variant or organ. For some variants, higher heteroplasmy generally correlates with more severe disease, but the relationship is not precise enough to predict an individual’s future from one percentage. The brain and heart may be affected at a burden that another tissue tolerates, and a blood percentage may not mirror either organ.

Three cautions make a heteroplasmy number easier to use correctly:

Name the tissue. “40% heteroplasmy” is incomplete without “in blood,” “in urine sediment,” or another source.
Check the method and detection limit. A value near the lower threshold may have more measurement uncertainty, and different laboratories may not produce directly interchangeable estimates.
Avoid a severity equation. Twice the percentage does not mean twice the symptoms. Age, tissue distribution, nuclear genetic background, environment, and the specific variant all influence expression.

Some variants, including common Leber hereditary optic neuropathy variants, are often homoplasmic yet do not affect every carrier. This shows that heteroplasmy is not the only source of incomplete penetrance. Sex, mitochondrial haplogroup, environmental exposures such as smoking, and other genetic factors may modify risk.

Large-scale deletions add another layer. A deletion may be abundant in skeletal muscle but absent or low in blood. A “negative” blood sequence result can therefore coexist with convincing clinical and muscle findings. Conversely, detecting a very low-level mtDNA change through highly sensitive sequencing does not automatically establish that it is clinically meaningful.

The most useful interpretation joins the laboratory number to the phenotype. A specialist asks whether the variant is established as pathogenic, whether the tissue is suitable, whether the measured burden is plausible for the presentation, and whether the family pattern supports the conclusion.

Maternal Inheritance and Family Risk

Mitochondrial DNA is usually inherited from the egg. A woman with an inherited mtDNA variant can pass it to children of any sex, while a man with an mtDNA variant generally does not transmit it through sperm. This is called maternal inheritance, but it should not be simplified to “all children have the same risk and severity.”

During egg formation, only a subset of the mother’s many mtDNA molecules contributes to each egg. This mitochondrial genetic bottleneck can produce substantial differences in heteroplasmy among eggs and therefore among siblings. A mother with mild symptoms may have a severely affected child, an unaffected child, or children with different presentations. For many heteroplasmic variants, a blood or urine level in the mother cannot provide an exact recurrence percentage for each pregnancy.

Family history may show affected people in several generations connected through women: a maternal grandmother, her children, and the children of her daughters. Yet the pattern can be hard to recognize because symptoms vary, onset may be late, and some carriers remain asymptomatic. A new, or de novo, mtDNA variant can also occur in one person without being detectable in the mother’s sampled tissue.

Not all changes involving mtDNA are maternally inherited:

A single large-scale mtDNA deletion is often sporadic, with a generally low but not zero recurrence risk for the mother of an affected child.
Multiple mtDNA deletions or mtDNA depletion commonly result from nuclear-gene variants and may follow autosomal recessive, autosomal dominant, or X-linked inheritance.
A mitochondrial disease caused by a nuclear gene follows that gene’s inheritance pattern rather than maternal inheritance.

This distinction is why testing relatives should begin with the exact molecular finding in the affected person whenever possible. Once a familial pathogenic variant is known, targeted testing can determine who carries it. Testing should still use an appropriate tissue and a sufficiently sensitive method.

Reproductive options depend on the variant, heteroplasmy, family history, local law, and personal values. They may include natural conception with prenatal diagnosis, in vitro fertilization with preimplantation genetic testing, use of donor eggs, adoption, or—in limited regulated settings—mitochondrial donation. Prenatal or embryo testing can be technically challenging because heteroplasmy in the sampled cells may not perfectly predict the level in every fetal tissue. Anyone considering these options should receive specialized reproductive genetics counseling rather than relying on a generic risk estimate. The broader principles of prenatal genetic testing still apply, but mtDNA requires additional laboratory and inheritance expertise.

Family communication can be emotionally difficult. A pathogenic mtDNA result is not anyone’s fault, and maternal transmission should not be framed as blame. A concise family letter from a genetics clinic can explain the finding, which relatives may benefit from evaluation, and how they can access testing without disclosing unnecessary medical details.

Next Steps After Testing

The best follow-up starts with the full report, not a portal notification. Request a copy that includes the gene and variant name, classification, heteroplasmy percentage, sample type, analytic method, detection threshold, and limitations. Then review it with the ordering clinician, a medical geneticist, genetic counselor, neurologist, metabolic specialist, or mitochondrial disease center as appropriate.

After a positive or likely positive result, a useful visit usually addresses five questions:

Does this variant fully or partly explain the clinical findings?
Which organs need baseline assessment or ongoing surveillance?
Are there medicines, anesthetic issues, prolonged fasting, dehydration, or other stresses that require a condition-specific plan?
Which relatives should be offered targeted testing, and from which tissue?
What does the result mean for future pregnancies?

Seek urgent medical care for acute neurologic changes, a new seizure, stroke-like symptoms, severe weakness, breathing difficulty, fainting, chest pain, persistent vomiting with dehydration, or a marked decline from baseline. A genetic result should not delay emergency evaluation.

After an uncertain result, avoid using the variant as the sole explanation for symptoms. Continue appropriate clinical care, document the phenotype carefully, and ask when reinterpretation is available. Updated family information, new symptoms, functional studies, or improved databases may change classification. A VUS can move toward pathogenic or benign over time, but many remain unresolved.

After a negative result, match the next step to the gap in the first test. Ask:

Was the entire mitochondrial genome sequenced or only selected variants?
What heteroplasmy level could the assay detect?
Were large deletions and mtDNA copy number assessed?
Was blood the only tissue tested?
Were nuclear mitochondrial genes analyzed?
Could the raw data be reanalyzed as gene-disease knowledge changes?

A broader genetic panel test may be suitable when symptoms point to a defined group of mitochondrial or overlapping disorders. Exome or genome sequencing may be more efficient when the presentation is broad. Biochemical studies, imaging, electrophysiology, muscle pathology, and other clinical tests can remain important even in the genomic era because they help establish organ involvement and evaluate alternative diagnoses.

Keep the original electronic and paper report. Variant names, tissue percentages, and assay details are more reliable than remembered summaries, and future clinicians need them to compare updated testing. Do not repeat a test solely because it is old; first determine whether reanalysis, a new sample, or a different technology addresses the original limitation.

An mtDNA test is most informative when treated as one piece of a combined clinical and genetic investigation. A well-supported positive result can end a long diagnostic search and guide family care. An uncertain or negative result can still be useful by showing which hypotheses remain open and which testing strategy should come next.

References

Disclaimer

This information is for education and does not diagnose mitochondrial disease or replace individualized medical advice. mtDNA results require interpretation by a qualified clinician or genetics professional who can consider the tested tissue, heteroplasmy, symptoms, family history, and assay limitations. Seek urgent care for sudden neurologic, cardiac, breathing, or severe metabolic symptoms.